Literature DB >> 17045756

Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease?

Marvin Arthur Karasek1.   

Abstract

Fibrosis is a major cause of human death and disability. It has been hypothesized widely that activation of resident tissue fibroblasts is responsible for the increase in matrix protein synthesis present in fibrotic tissue. More recent studies in vitro of the physiology of human dermal microvascular endothelial cells and their transformation into spindle-shaped cells by proinflammatory cytokines may provide a new explanation for the increase in myofibroblasts in fibrotic diseases. In cell culture human dermal microvascular endothelial cells transform reversibly into 2 distinct cell phenotypes observed in the endothelium in vivo: an epithelioid phenotype present in a homeostatic microvasculature and a more spindle-shaped phenotype present in an inflammed and a reactive microvasculature. When epithelioid endothelial cell cultures are exposed to proinflammatory cytokines typically increased in fibrosis in vivo (e.g. TNF-alpha and IL-beta) for sustained periods, epithelioid dermal microvascular endothelial cells transform into a spindle-shaped morphology. Many of the transformed cells are identified as myofibroblast-like cells by electron microscopy (cytoplasmic microfilaments with attachment plaques), matrix protein synthesis (type I collagen, alpha smooth muscle actin, calponin) and by RT-PCR analysis of matrix protein mRNA. Following injury to an endothelial cell culture a similar (but reversible) transformation into myofibroblast-like cells also is induced. Drugs known to slow the clinical progression to fibrosis in vivo (e.g. phosphodiesterase inhibitors, antibodies to inflammatory cytokines) are the the same drug types capable of inhibiting endothelial cell tranformation in vitro. The in vivo and in vitro observations made on blood vessel physiology and pathology following sustained inflammation support a hypothesis that endothelial cell transformation into myofibroblast-like cells may begin to explain the increase in matrix proteins and myofibroblasts pathognomonic of fibrotic disease. The experimental and clinical evidence leading to and supporting this hypothesis is presented and discussed in this report.

Entities:  

Mesh:

Year:  2006        PMID: 17045756     DOI: 10.1016/j.mehy.2006.07.053

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  10 in total

1.  Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.

Authors:  Y Sato; X S Ren; K Harada; M Sasaki; H Morikawa; S Shiomi; M Honda; S Kaneko; Y Nakanuma
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  Mechanisms of microvascular wound repair II. Injury induces transformation of endothelial cells into myofibroblasts and the synthesis of matrix proteins.

Authors:  Vaishali Chaudhuri; Marvin A Karasek
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Nov-Dec       Impact factor: 2.416

Review 3.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

4.  Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension.

Authors:  Azusa Kitao; Yasunori Sato; Seiko Sawada-Kitamura; Kenichi Harada; Motoko Sasaki; Hiroyasu Morikawa; Susumu Shiomi; Masao Honda; Osamu Matsui; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

Review 5.  The immunology of fibrosis: innate and adaptive responses.

Authors:  Georg Wick; Aleksandar Backovic; Evelyn Rabensteiner; Nadine Plank; Christian Schwentner; Roswitha Sgonc
Journal:  Trends Immunol       Date:  2010-01-26       Impact factor: 16.687

6.  Puerarin Protects against Cardiac Fibrosis Associated with the Inhibition of TGF-β1/Smad2-Mediated Endothelial-to-Mesenchymal Transition.

Authors:  Ya-Ge Jin; Yuan Yuan; Qing-Qing Wu; Ning Zhang; Di Fan; Yan Che; Zhao-Peng Wang; Yang Xiao; Sha-Sha Wang; Qi-Zhu Tang
Journal:  PPAR Res       Date:  2017-05-30       Impact factor: 4.964

Review 7.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

8.  Knockdown of CD146 promotes endothelial-to-mesenchymal transition via Wnt/β-catenin pathway.

Authors:  Zhao-Yu Zhang; Chao Zhai; Xue-Yuan Yang; Hai-Bing Li; Li-Ling Wu; Li Li
Journal:  PLoS One       Date:  2022-08-24       Impact factor: 3.752

9.  Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options.

Authors:  Olav A Gressner; Ralf Weiskirchen; Axel M Gressner
Journal:  Comp Hepatol       Date:  2007-07-30

Review 10.  Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases.

Authors:  Sonsoles Piera-Velazquez; Fabian A Mendoza; Sergio A Jimenez
Journal:  J Clin Med       Date:  2016-04-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.